BLK
BlackRock, Inc.
BLK has slightly lower modeled downside risk, despite its lower overall score.
CNS
Cohen & Steers, Inc.
CNS has the edge over BLK overall, supported by stronger valuation and stronger modeled upside.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
CNS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CNS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNS.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK's PE is in its expensive range at 28x.
CNS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $60.37 | -15% |
| Forward | 20x | $71.42 | — |
| Current | 22x | $71.42 | — |
| Fair | 25x | $80.45 | +13% |
| Expensive | 32x | $105 | +47% |
Historical ranges are pointers, not guarantees.
CNS has the edge over BLK in the historical PE scenario, which offers more potential upside but is not a forecast.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
CNS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNS's earnings to grow and its profitability to improve, with its revenue holding steady.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK earned $43.87 per share over the past year, up 11% from the year before.
CNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.64 | +12% |
| Q3 2026 | $3.25 | +1.9% |
| Q2 2026 | $3.25 | +3.2% |
| Q1 2026 | $3.02 | -1.3% |
| Q4 2025 | $2.97 | 0% |
| Q3 2025 | $3.19 | +19% |
| Q2 2025 | $3.15 | +23% |
| Q1 2025 | $3.06 | +19% |
| Q4 2024 | $2.97 | +14% |
CNS has the edge over BLK on earnings, with more consistent year-over-year improvement.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BLK has the edge over CNS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK's operating margin was 30% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2019.
CNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $157.4M | +11% |
| Q2 2026 | $152.7M | +12% |
| Q1 2026 | $145.6M | +8.3% |
| Q4 2025 | $143.8M | +2.9% |
| Q3 2025 | $141.7M | +6.4% |
| Q2 2025 | $136.1M | +12% |
| Q1 2025 | $134.5M | +9.6% |
| Q4 2024 | $139.8M | +17% |
CNS's revenue has grown year over year for 10 quarters in a row: $157M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -2.1 points |
| Q2 2026 | 35% | +2.7 points |
| Q1 2026 | 34% | +0.8 points |
| Q4 2025 | 28% | -7.3 points |
| Q3 2025 | 35% | +0.8 points |
| Q2 2025 | 32% | +0.3 points |
| Q1 2025 | 34% | +0.8 points |
| Q4 2024 | 35% | +3.5 points |
CNS has the edge over BLK on profitability, with a higher operating margin.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BLK has the stronger cash trend. Its trailing FCF is up 20% versus its history, compared with CNS at down 71%.
CNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20M | -62% |
| Q1 2026 | -$51.4M | +$58.7M |
| Q4 2025 | $776K | -98% |
| Q3 2025 | $52.6M | +117% |
| Q2 2025 | -$69.8M | -357% |
| Q1 2025 | -$110M | -20588% |
| Q4 2024 | $33.1M | -31% |
| Q3 2024 | $24.2M | -50% |
CNS's free cash flow was $22M over the past year, against −$122M the year before. Free cash flow isn't a meaningful measure for financial services companies like CNS.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has the edge over CNS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
CNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +253K shares |
| 1 year | +1.1% | +542K shares |
| 3 years | +5% | +2.5M shares |
| 5 years | +5.8% | +2.9M shares |
| Available history | +7% | +3.4M shares |
CNS has 52M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $358,000 |
| Q2 2026 | $394,000 |
| Q1 2026 | $16.9M |
| Q4 2025 | $1.6M |
| Q3 2025 | $258,000 |
| Q2 2025 | $621,000 |
| Q1 2025 | $26M |
| Q4 2024 | $1.5M |
CNS spent $19M buying back its own shares over the past year, down 32% from the year before.
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
CNS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
CNS has the edge over BLK on leverage, with a lower net debt burden relative to earnings.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
CNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.8 | Neutral |
| Stochastic | 33.9 | Neutral |
CNS's weekly RSI is 45 (neutral) and its Stochastic is 34 (neutral).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
CNS PE vs Financial Services Sector
| Metric | CNS | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 69% above |
| PE % | 33 | 63 | 30 pts below |
CNS has the edge over BLK on valuation relative to its sector.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK has the edge over CNS on trend strength, trading above more of its moving averages.
CNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 0.5% below |
| 20 week MA | $77.0 | 7.2% below |
| 50 week MA | $71.1 | 0.4% above |
| 100 week MA | $74.1 | 3.6% below |
| 200 week MA | $73.1 | 2.3% below |
CNS's trend is mixed: it's above one of its five weekly moving averages, and 2.3% below its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has the edge over CNS on returns for 2026, with the stronger performance.
CNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.7 | $73.4 | +17% |
| 2021 | $73.4 | $90.0 | +23% |
| 2022 | $90.0 | $63.2 | -30% |
| 2023 | $63.2 | $75.7 | +20% |
| 2024 | $75.7 | $93.4 | +23% |
| 2025 | $93.4 | $64.2 | -31% |
| 2026 YTD | $64.2 | $71.4 | +11% |
CNS has finished higher in four of the last six years. It's up 11% so far in 2026.